LivaNova initiated with an Equal Weight at Barclays

Barclays analyst Matt Miksic initiated coverage of LivaNova with an Equal Weight rating and $62 price target. The analyst says that while investors continue to anticipate the expansion of LivaNova’s Symmetry vagus nerve stimulation system into difficult to treat depression, he does not expect a material lift in coverage and adoption for depression until 2025 at the earliest. Major market expansion is still 2-3 years away for LivaNova, Miksic tells investors in a research note.